← Search & browse all drugs
MUSCULO-SKELETAL SYSTEM › DRUGS FOR TREATMENT OF BONE DISEASES › DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION › Other drugs affecting bone structure and mineralization
vosoritide
M05BX07
Forms & Strengths
- Lyophilized powder for injection: 0.4 mg, 0.56 mg, 1.2 mg per vial
Adult Dosing
- Not applicable; indicated for pediatric patients with achondroplasia whose epiphyses are not closed.
Pediatric Dosing
- Achondroplasia (epiphyses open): 15 mcg/kg subcutaneously once daily, administered in the abdomen.
- Adjust dosage based on actual body weight.
- Discontinue treatment upon confirmation of epiphyseal fusion.
Indications
- Improvement of linear growth in pediatric patients with achondroplasia and open epiphyses (generally aged 5 years and older).
Mechanism of Action
- C-type natriuretic peptide (CNP) analog.
- Binds to natriuretic peptide receptor-B (NPR-B), downregulating intracellular signaling via the fibroblast growth factor receptor 3 (FGFR3) pathway.
- Promotes endochondral ossification and increases linear bone growth.
Contraindications
- Hypersensitivity to vosoritide or any of its excipients.
Adverse Reactions
- Injection site reactions (erythema, swelling, urticaria)
- Blood pressure decrease (transient hypotension)
- Vomiting
- Gastroenteritis
- Arthralgia
- Dizziness
Drug Interactions
- No formal clinical drug-drug interaction studies have been conducted.
- Potential for additive blood pressure-lowering effects with antihypertensive medications.
Curated Content: Needs Vetting Before Put to Clinical Use